2268: WuXi XDC Cayman Inc. - Summary | Jitta

WuXi XDC Cayman Inc.

HKG:2268

Price
HK$57.85
Loss Chance
44.6%
6.10JITTA SCORE
59.87%Over Jitta Line
Jitta Ranking
60 / 226
433 / 2,473
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (68)
Recent Business Performance (78)
Financial Strength (79)
Return to Shareholders (30)
Competitive Advantage (72)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Recent IPOLess than 3 years
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
6.10
59.87%
3.78
269.87%
Life Sciences Tools and Services
4.86
132.06%
4.73
100.00%
3.70
26.22%
COMPANY DESCRIPTION
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.